Recent studies, including a series of articles coauthored by Jongstra-Bilen and Cybulsky, have brought fresh and exciting insight to the earliest stages of atherosclerotic plaque formation in mouse models of the disease. Capturing outstanding images of the lesser curvature of the murine aorta, a site highly prone to atherosclerotic plaque development, the Cybulsky laboratory revealed in 2006 that cells bearing markers of dendritic cells (DCs), including CD11c (αx integrin), take up residence just beneath the endothelium in the lesser curvature of mice.1 Possible counterparts of these DCs have also been observed in lesion-prone arterial sites of rabbits and humans.2 The initial appearance of murine DCs in the lesser curvature depends on endothelium activated in response to disturbed blood flow1,3 and is independent of plasma cholesterol status, because it occurs in standard mouse strains that are not hypercholesterolemic (Figure).1 These DCs were recently visualized in the CD11c-YFP mouse and shown to possess capacity for potent antigen presentation to T cells.4 Although they sit primarily beneath the endothelial lining, vascular DCs occasionally extend projections into the bloodstream (Figure).4 Even in the absence of hypercholesterolemia, the density of DCs within the lesser curvature of mice varies according to strain and positively correlates with the tendency of the strains to develop fulminant atherosclerosis under conditions of hypercholesterolemia.1 Moreover, the density of this population rapidly expands in the lesser curvature of low-density lipoprotein receptor (LDLR)−/− mice fed a high cholesterol diet for only a few days.1,5
Figure.
Role of dendritic cells in atherosclerotic plaque development and progression. CD11c+ DCs accumulate in the subintima of plaque-prone regions in the arterial tree, even in the absence of hypercholesterolemia in a manner that is partially dependent on vascular cell adhesion molecule 1, setting up a “preplaque sentinel post.” These CD11c+ DCs are comprised of at least 2 populations that can be distinguished based on differential expression of 33D1 and CD11b.5 33D1+ DCs proliferate locally in response to GM-CSF.5 Cholesterol feeding leads to lipid accumulation in vascular DCs that, as the feature article shows, function as a major reservoir for retaining cholesterol in nascent atherosclerotic plaques.10 This cholesterol accumulation triggers plaque progression. Over time, progressive plaques recruit large numbers of monocytes; some of these are CD11c+ in the mouse, and others are not.8 How and whether DCs, such as the proliferative 33D1+ DCs, participate in more progressed plaques remains to be explored. Intracellular lipid droplets here depicted as white circles in the cytoplasm of schematized cell types.
CD11c is not an exclusive marker of DCs but can also be found on macrophages.6,7 However, other features set at least some of the vascular DCs apart from macrophages. For instance, the intimal increase of this population in response to cholesterol feeding is substantially affected by local granulocyte/macrophage colony-stimulating factor (GM-CSF)–driven proliferation, rather than by solely building up after recruitment of blood-borne precursors (Figure). In particular, the proliferating DCs appear unrelated in origin to Ly-6Chi monocytes, thereby distinguishing them from many plaque macrophages, which arise from Ly-6Chi monocytes.8,9 Thus, the widely held view that monocytes are the earliest immune cell to contribute to and promote the development of atherosclerotic plaques may need revision. Instead, vascular DCs may act earlier than monocytes in the sequence of events that lead to plaque development. Now, in this issue of Circulation Research, Jongstra-Bilen, Cybulsky, and colleagues reveal that vascular DCs have a key role in the earliest accumulation of cholesterol in the aortic wall (Figure).10
Here, the authors continued with their work in the LDLR−/− mouse model, in which feeding of a cholesterol-enriched diet for only a few days leads to neutral lipid deposition in the lesser curvature. First, they show that this lipid resides within CD11c+ cells. Then, to examine functional significance, they used a popular method to deplete CD11c+ cells, using a strain of mice that expresses diphtheria toxin receptor (DTR) under control of the CD11c promoter (CD11c-DTR),11 here interbred with LDLR−/− mice. A single diphtheria toxin (DT) injection removed essentially all subintimal immune cells in these mice for about 1 week, allowing the authors to ask whether lipid would accumuate subintimally if CD11c+ cells were not present. Following DT-mediated depletion, LDLR−/− mice were fed a high-fat diet for 5 days, and they compared lipid accumulation (reasonably assumed to be cholesterol) in the lesser curvature of these mice with that of nondepleted controls. There was a striking 55% reduction in early lipid accumulation in the aortic wall in the absence of CD11c+ cells, and the lipid that did accumulate was found only in extracellular spaces, apparently ignored by circulating monocytes, at least momentarily. Thus, these data argue that vascular DCs importantly regulate the accumulation of lipid in the earliest stages of plaque formation.
We are left pondering the heterogeneity and origin of these vascular DCs. How different are these cells from monocyte-derived macrophage foam cells in development and function? Although at least a portion of vascular DCs do not arise from Ly-6Chi monocytes,5 their overall relationship to the monocyte lineage, widely accepted as precursors of macrophages, is uncertain. One of the important DC markers that the authors identified on the cells was 33D1.5 33D1 is not expressed on all DC types and has mainly been described as a marker of a portion of spleen DCs that is even absent on lymph node or Peyer’s Patch DCs.12,13 In spleen, 33D1 identifies splenic DCs that preferentially mediate CD4+ T cell responses.14 Thus, given our present body of knowledge, it is particularly unusual to observe 33D1 on a DC population outside the spleen. Because it is clear that many DCs, including spleen DCs, are not derived from monocytes,15–18 it may indeed be the case that these cells are not within the monocyte lineage. On the other hand, there is evidence that vascular DCs are not the phenotypic equivalents of spleen DCs.4
Even more importantly, are all vascular CD11c+ cells involved in retaining lipid in the artery wall, or is this role held only by a subset of the DCs described? In their previous work, the authors reveal heterogeneity among vascular DCs,5 although this is scarcely discussed in the present study. Thus, 33D1 is a marker of many, but not all, vascular DCs.5 Another fraction of CD11c+ DCs in nascent plaques are CD11b+ cells4,5 that likely arise from Ly-6Chi monocytes.5 These monocyte-derived cells accumulate in nascent plaques simultaneously with the proliferation of 33D1+ vascular DCs.5 Apparently, DT treatment affected both of these populations in the CD11c-DTR mouse. In contrast to CD11c, neither the 33D1 nor CD11b marker was demonstrated to colocalize with lipid staining, so it remains unclear whether the possibly more DC-related 33D1+ cells accumulated lipid or whether it was in the CD11b+ cells, or both. The LysCre reporter mouse provides a useful approach for confirming which DC populations are not of monocyte origin17,18 and would be useful to apply here. Furthermore, application of CD11b-DTR mice would potentially allow for the removal of CD11b+ DCs, but not 33D1+ DCs, to determine whether these different DC populations have distinct roles with regard to the accumulation of cholesterol in the artery wall. In addition, use of other DTR models besides the CD11c-DTR mouse model, especially DTR models in which no changes in lipid deposition are found, would help to ensure that any spike in TGFβ1 released from DTR-induced apoptosis did not account for the changes in lipid deposition observed.
In summary, the appearance of vascular DCs in lesion-prone areas of arteries before the onset of hypercholesterolemia1 had already positioned these cells as suspect players in disease initiation. Now, the findings of the present study,10 together with images of vascular DCs extending projections into the lumen of the aorta,4 raise the tantalizing question of whether vascular DCs actually capture LDL that may interact with the activated endothelium as it flows past in the circulation, thereby collecting much of the first cholesterol that accumulates in the arterial intima. Because at least some DCs can retain intact protein for long periods after ingesting it,19–21 in contrast to macrophages,20 the idea that DCs are the earliest depot of cholesterol deposition in plaques may not be inconsistent with earlier studies that cholesterol accumulation in nascent plaques of rabbits involves selective retention of “intact” LDL within plaque-prone sites,22,23 even though those studies argued against the idea that the earliest plaque cholesterol was localized within phagocytes. To potentially reconcile the present study with the aforementioned earlier work in rabbits and add to our understanding of the sequence of early events in plaque formation, it will be interesting in future studies to determine whether vascular DCs indeed retain LDL-associated proteins in intact form for rather long periods. It will also be important to understand how this mechanism interfaces with lipoprotein retention mediated by proteoglycans in the artery wall24,25 and whether DC-versus proteoglycan-mediated retention operate cooperatively, possibly even through a positive feedback, to bring on rapid plaque growth or whether they represent independent mechanisms for cholesterol retention in the artery wall. In either case, vascular DCs, likely activated in response to lipid loading, would be in a position to produce a cascade of factors that orchestrate the recruitment of large numbers of monocytes and increased amounts of cholesterol that follow, thereby fueling plaque progression in a way that proteoglycan-mediated cholesterol retention alone may not. We eagerly wait for the next chapter in this series of studies to unfold.
Acknowledgments
Sources of Funding
Work by the authors is supported by NIH grants AI049653, AI061741, and HL084312 and American Heart Association Established Investigator Award 0740052 (to G.J.R.). S.P. has been supported by Fondation pour la Recherche Medicale (France), a 2007 Norman Alpert Visiting Scientist Award from the European Society of Cardiology/American Heart Association, and a grant from the Experimental Therapeutics Institute, Mount Sinai Hospital.
Non-standard Abbreviations and Acronyms
- DC
dendritic cell
- DT
diptheria toxin
- DTR
diptheria toxin receptor
- GM-CSF
granulocyte/macrophage colony-stimulating factor
- LDL
low-density lipoprotein
- LDLR
low-density lipoprotein receptor
Footnotes
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
Disclosures
None.
References
- 1.Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med. 2006;203:2073–2083. doi: 10.1084/jem.20060245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Millonig G, Niederegger H, Rabl W, Hochleitner BW, Hoefer D, Romani N, Wick G. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol. 2001;21:503–508. doi: 10.1161/01.atv.21.4.503. [DOI] [PubMed] [Google Scholar]
- 3.Mullick AE, Soldau K, Kiosses WB, Bell TA, III, Tobias PS, Curtiss LK. Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med. 2008;205:373–383. doi: 10.1084/jem.20071096. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Choi JH, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS, Bozzacco L, Trumpfheller C, Park CG, Steinman RM. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med. 2009;206:497–505. doi: 10.1084/jem.20082129. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Zhu SN, Chen M, Jongstra-Bilen J, Cybulsky MI. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. J Exp Med. 2009;206:2141–2149. doi: 10.1084/jem.20090866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest. 2007;117:89–93. doi: 10.1172/JCI30992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol. 2008;19:462–468. doi: 10.1097/MOL.0b013e32830d5f09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185–194. doi: 10.1172/JCI28549. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195–205. doi: 10.1172/JCI29950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Paulson KE, Zhu S, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ Res. 2010;106:383–390. doi: 10.1161/CIRCRESAHA.109.210781. [DOI] [PubMed] [Google Scholar]
- 11.Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17:211–220. doi: 10.1016/s1074-7613(02)00365-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Witmer MD, Steinman RM. The anatomy of peripheral lymphoid organs with emphasis on accessory cells: light-microscopic immunocyto-chemical studies of mouse spleen, lymph node, and Peyer’s patch. Am J Anat. 1984;170:465–481. doi: 10.1002/aja.1001700318. [DOI] [PubMed] [Google Scholar]
- 13.Schuler G, Romani N, Steinman RM. A comparison of murine epidermal Langerhans cells with spleen dendritic cells. J Invest Dermatol. 1985;85:99s–106s. doi: 10.1111/1523-1747.ep12275566. [DOI] [PubMed] [Google Scholar]
- 14.Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, Steinman RM, Nussenzweig MC. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315:107–111. doi: 10.1126/science.1136080. [DOI] [PubMed] [Google Scholar]
- 15.Fogg DK, Sibon C, Miled C, Jung S, Aucouturier P, Littman DR, Cumano A, Geissmann F. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science. 2006;311:83–87. doi: 10.1126/science.1117729. [DOI] [PubMed] [Google Scholar]
- 16.Varol C, Landsman L, Fogg DK, Greenshtein L, Gildor B, Margalit R, Kalchenko V, Geissmann F, Jung S. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med. 2007;204:171–180. doi: 10.1084/jem.20061011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Jakubzick C, Bogunovic M, Bonito AJ, Kuan EL, Merad M, Randolph GJ. Lymph-migrating, tissue-derived dendritic cells are minor constituents within steady-state lymph nodes. J Exp Med. 2008;205:2839–2850. doi: 10.1084/jem.20081430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, Yao K, Chu FF, Randolph GJ, Rudensky AY, Nussenzweig M. In vivo analysis of dendritic cell development and homeostasis. Science. 2009;324:392–397. doi: 10.1126/science.1170540. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol. 2005;23:975–1028. doi: 10.1146/annurev.immunol.22.012703.104538. [DOI] [PubMed] [Google Scholar]
- 20.Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005;307:1630–1634. doi: 10.1126/science.1108003. [DOI] [PubMed] [Google Scholar]
- 21.Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med. 2000;191:927–936. doi: 10.1084/jem.191.6.927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis. 1989;9:895–907. doi: 10.1161/01.atv.9.6.895. [DOI] [PubMed] [Google Scholar]
- 23.Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis. 1989;9:908–918. doi: 10.1161/01.atv.9.6.908. [DOI] [PubMed] [Google Scholar]
- 24.Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551–561. doi: 10.1161/01.atv.15.5.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750–754. doi: 10.1038/nature00804. [DOI] [PubMed] [Google Scholar]

